Internal Report 14: “34 Blood Vessel Inflammation, Vasculitis, Adverse Events Occurred in First 90 Days After Pfizer mRNA “Vaccine” Rollout, Including One Fatality. Half Had Onset Within Three Days of Injection. 81% of Sufferers Were Women.”

The WarRoom/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1)—Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt—wrote an important review of vasculitis adverse events found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6“). The search criterion for this System Organ Class was “Vasculitides.” Vasculitis, a.k.a., vasculitides, is inflammation of a blood vessel or multiple blood vessels. Small or large vessels may be involved, and symptoms vary depending on organ involvement. The inflammation can be related to a direct immune attack on the cells of the blood vessel or to deposits of complexes of antibody and an antigen (virus or other protein) that is not part of the blood vessel itself. It is important to note that the adverse events (AEs) in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product. Highlights of this report include:

• 34 vasculitis adverse events were reported among 32 cases (i.e., patients). One adverse event was fatal.
• 81% of vasculitis sufferers were women, and 19% were men.
• Onset time from injection to symptom onset was <24 hours to 19 days, with half occurring within three days of receiving the vaccine.
• Systemic vasculitis is difficult to treat. It often cannot be cured and can require permanently being on medication to manage it.
• 32% of vasculitis adverse events were related to skin rashes, including cutaneous vasculitis, vasculitic rash, hypersensitivity vasculitis, and palpable purpura.
• 35% of these adverse events were marked as “not resolved” at the end of the post-marketing period.
• Pfizer received reports of three cases of Giant cell arteritis, a serious autoimmune disease of the large blood vessels that can lead to blindness if not quickly treated.
• Three cases of peripheral ischemia, inflammation of blood vessels to the point of impairing blood flow, were reported.

[IMAGE 1 — ORIGINAL SOURCE PAGE 169; PLACE AFTER THE TEXT ABOVE]

•Two instances of Behçet’s syndrome—a type of vasculitis with mouth, skin, and genital sores, often accompanied by eye inflammation and blood clots—were reported.

• One instance of Takayasu’s arteritis, a very serious and rare disease where the aorta and its main branches are typically inflamed—was recorded.

Pfizer concluded, “This case review does not raise new safety issues. Surveillance will continue.” Please read this important report below.

[IMAGE 2 — ORIGINAL SOURCE PAGE 170; PLACE AFTER THE TEXT ABOVE]

[IMAGE 3 — ORIGINAL SOURCE PAGE 171; PLACE AFTER THE TEXT ABOVE]

[IMAGE 4 — ORIGINAL SOURCE PAGE 172; PLACE AFTER THE TEXT ABOVE]